Company intelligence / Profile preview

Unichem Pharmaceuticals

East Brunswick, New Jersey, United Statesunichemusa.com ↗

Ownership: Private
Employees: ~3100
Development stage: Commercial

Overview

Unichem has a broad commercial portfolio of US FDA, ANVISA, and EMA-approved generic drugs in psychiatry, neurology, cardiology, and other indications. It also runs biotechnology R&D for biosimilars, though all publicly reported proprietary NCE/NBEs are discontinued. Over 45 ANDA approvals in the US and >60 European submissions indicate established generics and biosimilar commercial success, not new chemical entity development.

Therapeutic areas: EndocrinologyPsychiatryDermatologyCardiovascularOncologyNeurology
Modalities: Small moleculeBiologicBiosimilar
Industry: Biotech

Drug pipeline

1 asset

cyclobenzaprine

Commercial

Indications: Muscle spasm

Beyond the preview

Go deeper on Unichem Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unichem Pharmaceuticals.

Explore the full profile